Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Depreciation & Amortization (CF) (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Depreciation & Amortization (CF) for 17 consecutive years, with $12.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Depreciation & Amortization (CF) fell 14.86% to $12.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $53.7 million, a 12.25% decrease, with the full-year FY2025 number at $53.7 million, down 12.25% from a year prior.
  • Depreciation & Amortization (CF) was $12.6 million for Q4 2025 at Myriad Genetics, roughly flat from $12.6 million in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $19.4 million in Q1 2023 to a low of $12.6 million in Q3 2025.
  • A 5-year average of $14.6 million and a median of $14.2 million in 2021 define the central range for Depreciation & Amortization (CF).
  • Peak YoY movement for Depreciation & Amortization (CF): tumbled 62.85% in 2021, then skyrocketed 49.23% in 2023.
  • Myriad Genetics' Depreciation & Amortization (CF) stood at $13.3 million in 2021, then grew by 3.01% to $13.7 million in 2022, then rose by 10.22% to $15.1 million in 2023, then dropped by 1.99% to $14.8 million in 2024, then dropped by 14.86% to $12.6 million in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Depreciation & Amortization (CF) are $12.6 million (Q4 2025), $12.6 million (Q3 2025), and $14.1 million (Q2 2025).